JPRN-UMIN000021544Recruiting未知
Evaluation of the effectiveness and safety of Sofosbuvir plus Daclatasvir in the treatment for HCV or HIV/HCV with hemophilia - SOF+DCV for HCV with hemophilia
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Tokyo Medical University
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •HCV-genotype is only GT1 or GT2. Subjects with un-compensate cirrhosis Serious renal dysfunction (eGFR<30ml/min/1.73m2) Positive of HBs antigen QTcF 500>msec or second/thrid degree of AV-block in ECG Have active oppotunistic infection required treatment. The following concomitant medications are not permitted : Rifampicin, Rifabutin, Phenytoin, Carbamazepine, Phenobarbital, Dexamethasone (given whole body), St. John's wort. In the opinion of the Investigator makes the subject unsuitable for enrollment.
Investigators
Similar Trials
Completed
Phase 3
Safety and efficacy of sofosbuvir in the moderate COVID19COVID19.Coronavirus infection, unspecifiedU07.1IRCT20180302038915N1Shahid Beheshti University of Medical Sciences50
Not yet recruiting
Not Applicable
Sodium hyaluronate 2% (Pen Injector) and Restylane Vital (PFS) for Skin Rejuvenation of Dorsal HandsCTRI/2019/03/018015Virchow Biotech Private Limited
Recruiting
Not Applicable
The assessment of effectiveness and safety of Nozovent Anti-Snoring Spray for snore patientssnoringJPRN-UMIN000010713Department of Otolaryngology, Yamaguchi University Graduate School of Medicine20
Completed
Phase 2
The study evaluating the efficacy and safety of sorafenib in patients with differentiated thyroid cancer not amendable to radioactive iodine therapy and other alternative treatment.Thyroid cancerJPRN-UMIN000017777niversity of Tsukuba47
Recruiting
Phase 1
Investigating the solution containing herbal exosomes in comparison with Wharton jelly stem cell exosomes and 5% minoxidil in the treatment of hair loss.IRCT20200127046282N53Tehran University of Medical Sciences30